Compared with those in normal tissues, YTHDC2 expression levels were significantly downregulated in 7 types of cancer, including LUAD and LUSC (Figure 1A), ovarian serous cystadenocarcinoma, testicular germ cell tumor, thyroid carcinoma, uterine corpus endometrial carcinoma and uterine carcinosarcoma, while they were increased in lymphoid neoplasm diffuse large B-cell lymphoma and thymoma (Figure S1). Here, YTHDC2 is linked to uterine carcinosarcoma.